Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.

Abstract

The efficacy of telithromycin has been assessed in six Phase III studies involving adults with mild to moderate community-acquired pneumonia (CAP) with a degree of severity compatible with oral therapy. Patients received telithromycin 800 mg once daily for 7-10 days in three open-label studies (n=870) and three randomized, double-blind, comparator-controlled studies (n=503). Comparator antibacterials were amoxicillin 1000 mg three-times daily, clarithromycin 500 mg twice daily and trovafloxacin 200 mg once daily. Clinical and bacteriological outcomes were assessed 7-14 days post-therapy. Among telithromycin-treated patients, per-protocol clinical cure rates were 93.1 and 91.0% for the open-label and comparative studies, respectively. Telithromycin treatment was as effective as the comparator agents. High eradication and clinical cure rates were observed for infections caused by key pathogens: Streptococcus pneumoniae including isolates resistant to penicillin G and/or erythromycin A (95.4%), Haemophilus influenzae (89.5%) and Moraxella catarrhalis (90%). Telithromycin was also highly effective in patients with infections caused by atypical and/or intracellular pathogens and those at increased risk of morbidity. Telithromycin was generally well tolerated. Telithromycin 800 mg once daily for 7-10 days offers a convenient and well-tolerated first-line oral therapy for the empirical treatment of mild to moderate CAP.

• Authors: L Hagberg, C Carbon, D J van Rensburg, C Fogarty, L Dunbar, J Pullman
• Journal: Respiratory medicine (Respir Med) Vol. 97 Issue 6 Pg. 625-33 (Jun 2003) ISSN: 0954-6111 [Print] England
• PMID: 12814146 (Publication Type: Journal Article, Meta-Analysis)

Chemical References

• Anti-Bacterial Agents
• Anti-Infective Agents
• Fluoroquinolones
• Ketolides
• Macrolides
• Naphthyridines
• Penicillins
• Amoxicillin
• trovafloxacin
• Clarithromycin
• telithromycin

Topics

• Aged
• Amoxicillin (administration & dosage)
• Anti-Bacterial Agents (administration & dosage)
• Anti-Infective Agents (administration & dosage)
• Clarithromycin (administration & dosage)
• Clinical Trials, Phase III as Topic
• Community-Acquired Infections (drug therapy)
• Double-Blind Method
• Fluoroquinolones
• Humans
• Ketolides
• Macrolides
• Naphthyridines (administration & dosage)
• Penicillins (administration & dosage)
• Pneumonia, Bacterial (drug therapy)
• Randomized Controlled Trials as Topic
• Treatment Outcome